About this trial
The goal of this clinical trial is to learn which is better, combining Dexmedetomidine infusion and paragastric neural block or combining laparoscopic TAP block and paragastric neural block to enhance recovery after laparoscopic sleeve gastrectomy.
The main questions it aims to answer are:
Will using paragastric neural block (PGNB) combined with dexmedetomidine infusion give better recovery or using PGNB combined with laparoscopic transversus abdominis plane (LTAP) block in patients undergoing laparoscopic sleeve gastrectomy.
This will be assessed by:
Recording how much opioids were consumed by the patients Hemodynamic stability of the enrolled patients Pain scores as given by the patient The quality of postoperative patient recovery How many patients encountered nausea or vomiting
Eligibility criteria
Qualifiers
American Society of Anesthesiologists (ASA) physical status II- III
BMI 35- 50 kg/m2
Disqualifiers
Significant hepatic, renal, neuromuscular, or cardiac impairments
Extreme obesity (BMI > 50 kg/m2)
Patients on current opioid medication
Allergies to dexmedetomidine or bupivacaine
Trial design
Treatments tested in this trial
- Dexmedetomidine infusion
- Paragastric neural block
- Laparoscopic Transversus Abdominis Plane (LTAP) block